ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Pretreatment radiomic biomarker for immunotherapy responder prediction in stage IB-IV NSCLC (LCDigital-IO Study): a multicenter retrospective study

Wu, Shaowei; Zhan, Weijie; Liu, Lan; Xie, Daipeng; Yao, Lintong; Yao, Henian; Liao, Guoqing; Huang, Luyu; Zhou, Yubo; You, Peimeng; Huang, Zekai; Li, Qiaxuan; Xu, Bin; Wang, Siyun; Wang, Guangyi; Zhang, Dong-Kun; Qiao, Guibin; Chan, Lawrence Wing-Chi; Lanuti, Michael; Zhou, Haiyu*广东省人民医院; 广东医学院; 南方医科大学; 汕头大学
Journal for ImmunoTherapy of Cancer2023-10DOI: 10.1136/jitc-2023-007369
10阅读
引用收藏
分享

摘要

BackgroundThe predictive efficacy of current biomarker of immune checkpoint inhibitors (ICIs) is not sufficient. This study investigated the causality between radiomic biomarkers and immunotherapy response status in patients with stage IB-IV non-small cell lung cancer (NSCLC), including its biological context for ICIs treatment response prediction.MethodsCT images from 319 patients with pretreatment NSCLC receiving immunotherapy between January 2015 and November 2021 were retrospectively collected and composed a discovery (n=214), independent validation (n=54), and external test cohort (n=51). A set of 851 features was extracted from tumorous and peritumoral volumes of interest (VOIs). The reference standard is the durable clinical benefit (DCB, sustained disease control for more than 6 months assessed via radiological evaluation). The predictive value of combined radiomic signature (CRS) for pathological response was subsequently assessed in another cohort of 98 patients with resectable NSCLC receiving ICIs preoperatively. The association between radiomic features and tumor immune landscape on the online data set (n=60) was also examined. A model combining clinical predictor and radiomic signatures was constructed to improve performance further.ResultsCRS discriminated DCB and non-DCB patients well in the training and validation cohorts with an area under the curve (AUC) of 0.82, 95% CI: 0.75 to 0.88, and 0.75, 95% CI: 0.64 to 0.87, respectively. In this study, the predictive value of CRS was better than programmed cell death ligand-1 (PD-L1) expression (AUC of PD-L1 subset: 0.59, 95% CI: 0.50 to 0.69) or clinical model (AUC: 0.66, 95% CI: 0.51 to 0.81). After combining the clinical signature with CRS, the predictive performance improved further with an AUC of 0.837, 0.790 and 0.781 in training, validation and D2 cohorts, respectively. When predicting pathological response, CRS divided patients into a major pathological response (MPR) and non-MPR group (AUC: 0.76, 95% CI: 0.67 to 0.81). Moreover, CRS showed a promising stratification ability on overall survival (HR: 0.49, 95% CI: 0.27 to 0.89; p=0.020) and progression-free survival (HR: 0.43, 95% CI: 0.26 to 0.74; p=0.002).ConclusionBy analyzing both tumorous and peritumoral regions of CT images in a radiomic strategy, we developed a non-invasive biomarker for distinguishing responders of ICIs therapy and stratifying their survival outcome efficiently, which may support the clinical decisions on the use of ICIs in advanced as well as patients with resectable NSCLC.

学科与关键词

关键词
immunotherapytumor biomarkersnon-small cell lung cancer
相关
加载中…
  • Pretreatment radiomic biomarker for immunotherapy responder prediction in IB-IV stage NSCLC: A multi-center retrospective study
    Wu, Shaowei; Zhou, HaiYu; Xie, Daipeng; Yao, LintongAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
  • Development of Radiomic-Based Model to Predict Clinical Outcomes in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy
    Tankyevych, Olena; Trousset, Flora; Latappy, Claire; Berraho, Moran; Dutilh, Julien; Tasu, Jean Pierre; Lamour, Corinne; Cheze Le Rest, CatherineCancers, 2022, 14(23): 5931.被引 10
  • A Novel Multiparameter Biomarker of Pathological Response for NSCLC Receiving Neoadjuvant Immunotherapy: A Real-world Study
    Wu, S.; Zhou, H.; Zhan, W.
查看全部 →

发表信息

论文状态
公开发表
期刊
Journal for ImmunoTherapy of Cancer
发表日期
2023-10
卷期
第 11 卷, 第 10 期
页码
e007369
DOI
10.1136/jitc-2023-007369
成果收录
SCIE
资助标注
International Science and Technology Cooperation Program of Guangdong [2022A0505050048]; Natural Science Foundation of Guangdong [2021A1515010838]; Science and Technology Program of Guangzhou [201903010028]; Beijing Xisike Clinical Oncology Research Foundation [Y-HS202102-0038]

作者

  • W

    Wu, Shaowei (第一作者)

    guangdong prov peoples hosp · southern med univ

  • Z

    Zhan, Weijie

    guangdong prov peoples hosp · southern med univ

查看全部 20 位作者收起作者
  • L

    Liu, Lan

    jiangxi canc hosp

  • X

    Xie, Daipeng

    guangdong prov peoples hosp · southern med univ

  • Y

    Yao, Lintong

    guangdong prov peoples hosp · southern med univ · shantou univ

  • Y

    Yao, Henian

    guangdong med univ · guangdong prov peoples hosp · southern med univ

  • L

    Liao, Guoqing

    shantou univ

  • H

    Huang, Luyu

  • Z

    Zhou, Yubo

    guangdong prov peoples hosp · southern med univ

  • Y

    You, Peimeng

    jiangxi canc hosp

  • H

    Huang, Zekai

    guangdong med univ

  • L

    Li, Qiaxuan

    guangdong prov peoples hosp · southern med univ · shantou univ

  • X

    Xu, Bin

    guangdong prov peoples hosp · southern med univ

  • W

    Wang, Siyun

    guangdong prov peoples hosp · southern med univ

  • W

    Wang, Guangyi

    guangdong prov peoples hosp · southern med univ

  • Z

    Zhang, Dong-Kun

    guangdong prov peoples hosp · southern med univ

  • Q

    Qiao, Guibin

    guangdong prov peoples hosp · southern med univ

  • C

    Chan, Lawrence Wing-Chi

    hong kong polytech univ

  • L

    Lanuti, Michael

  • Z

    Zhou, Haiyu (通讯)

    guangdong prov peoples hosp · southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417